P16 alterations increase the metastatic potential of endometrial carcinoma

Gynecologic Oncology

Volumn 111, Issue 2, 2008, Pages 365-371

  Ignatov, Atanas ^a   Bischoff, Joachim ^a   Schwarzenau, Christa ^a   Krebs, Thomas ^a   Kuester, Doerthe ^a   Herrmann, Kerstin ^a   Costa, Serban D ^a   Roessner, Albert ^a   Semczuk, Andrzej ^b   Schneider Stock, Regine ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Endometrial carcinoma; Gene alteration; Hypermethylation; Metastasis; P16

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE DELETION; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC;

EID: 55649096866     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.037     Document Type: Article

References (21)

1. Serrano J., Goebel S.U., Peghini P.L., Lubensky I.A., Gibril F., and Jensen R.T. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 85 (2000) 4146-4156
2. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
3. Kamb A. Cyclin-dependent kinase inhibitors and human cancer. Curr Top Microbiol Immunol 227 (1998) 139-148
4. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., Yim S.F., Lai K.W., et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol Oncol 65 (1997) 319-324
5. Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., Demetrick D.J., et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55 (1995) 1448-1451
6. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55 (1995) 4525-4530
7. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11 (1995) 210-212
8. Salvesen H.B., Das S., and Akslen L.A. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6 (2000) 153-159
9. Nakashima R., Fujita M., Enomoto T., Haba T., Yoshino K., Wada H., et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 80 (1999) 458-467
10. Semczuk A., Boltze C., Marzec B., Szczygielska A., Roessner A., and Schneider-Stock R. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol 129 (2003) 589-596
11. Hatta Y., Hirama T., Takeuchi S., Lee E., Pham E., Miller C.W., et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol 154 (1995) 1954-1957
12. Milde-Langosch K., Riethdorf L., Bamberger A.M., and Loning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 434 (1999) 23-28
13. Deligdisch L., Kase N.G., and Bleiweiss I.J. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 46 (2000) 17-21
14. Shiozawa T., Nikaido T., Shimizu M., Zhai Y., and Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 80 (1997) 2250-2256
15. Geradts J., Fong K.M., Zimmerman P.V., Maynard R., and Minna J.D. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5 (1999) 791-800
16. Tsuda H., Yamamoto K., Inoue T., Uchiyama I., and Umesaki N. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer 82 (2000) 675-682
17. Peiffer S.L., Bartsch D., Whelan A.J., Mutch D.G., Herzog T.J., and Goodfellow P.J. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog 13 (1995) 210-212
18. Engelsen I.B., Stefansson I., Akslen L.A., and Salvesen H.B. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 195 (2006) 979-986
19. Heppner G.H. Tumor heterogeneity. Cancer Res 44 (1984) 2259-2265
20. Konemann S., Schuck A., Malath J., Rupek T., Horn K., Baumann M., et al. Cell heterogeneity and subpopulations in solid tumors characterized by simultaneous immunophenotyping and DNA content analysis. Cytometry 41 (2000) 172-177
21. Bernards R., and Weinberg R.A. A progression puzzle. Nature 418 (2002) 823